ESG22 Aug 2026, 02:00 pm
Mankind Pharma ESG Rating Improves to 'Strong' with 64 Score
AI Summary
Mankind Pharma Ltd has announced an improved ESG Rating of 64, placing it in the 'Strong' category, up from a previous rating of 57 ('Adequate'). The company's Core ESG Rating also saw an increase to 71 from 60. CRISIL ESG Ratings & Analytics independently assigned this rating based on FY2026 disclosures and publicly available information, without direct engagement from the company. This positive development highlights the company's enhanced environmental, social, and governance performance.
Key Highlights
- Mankind Pharma's ESG Rating improved to 64 ('Strong').
- Previous ESG Rating was 57 ('Adequate').
- Core ESG Rating increased to 71 from 60.
- Rating assigned independently by CRISIL ESG Ratings.
- Rating based on FY2026 disclosures and public information.
Price Impact
More from MANKIND